{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:05:21Z","timestamp":1772294721624,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["JPMH21HA2011"],"award-info":[{"award-number":["JPMH21HA2011"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mucormycosis is a potentially fatal fungal infection, and there is limited information on its precise epidemiology and treatment practices, including the optimal dosage of liposomal amphotericin B.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective, multicenter, nationwide analysis of 82 proven and probable cases of mucormycosis was performed. Cases between 2015 and 2022 were collected from 51 hospitals in Japan by hematologists and infectious disease specialists. The study included the epidemiology, treatment details, and association between the dose of liposomal amphotericin B and the outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The lungs were the most commonly involved organ (70.7% of cases), and 35.4% of patients had disseminated disease. Rhizopus spp., Cunninghamella spp., and Mucor spp. were the most common organisms. Mortality at 4 weeks was 41.5%. The survivors had a shorter duration of neutropenia (P = .006) and less persistent hyperglycemia (P = .023). The site of infection and species of Mucorales had no detectable effect on survival. Survival did not differ between patients receiving liposomal amphotericin B at 5\u2005mg\/kg\/d relative to those receiving &amp;gt;5\u2005mg\/kg\/d (P = .625). Using Cox proportional hazards models and adjusting for confounders, the hazard ratio for the influence of &amp;gt;5\u2005mg\/kg\/d liposomal amphotericin B on 4-week survival was 0.86 (95% CI, 0.28\u20132.68; P = .796) compared with 5\u2005mg\/kg\/d.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study provides important insights into the precise epidemiology and treatment practices of mucormycosis. Treatment with liposomal amphotericin B at doses higher than 5\u2005mg\/kg\/d did not improve outcomes relative to 5\u2005mg\/kg\/d.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad480","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T21:01:29Z","timestamp":1695416489000},"source":"Crossref","is-referenced-by-count":4,"title":["Prognostic Association of Liposomal Amphotericin B Doses Above 5\u2005mg\/kg\/d in Mucormycosis: A Nationwide Epidemiologic and Treatment Analysis in Japan"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-7679","authenticated-orcid":false,"given":"Masato","family":"Tashiro","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan"},{"name":"Infection Control and Education Center, Nagasaki University Hospital , Nagasaki , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hotaka","family":"Namie","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , Nagasaki , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-5386","authenticated-orcid":false,"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan"},{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , Nagasaki , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kakeya","sequence":"additional","affiliation":[{"name":"Department of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitsugu","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Fungal Infection, National Institute of Infectious Disease , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital , Nagasaki , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University Hospital , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukuda","family":"Tomoo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Saitama Medical Center, Saitama Medical University , Saitama , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toho University Omori Medical Center , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan"},{"name":"Infection Control and Education Center, Nagasaki University Hospital , Nagasaki , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"2023100510362977200_ofad480-B1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(10)70316-9","article-title":"Mucormycosis: its contemporary face and management strategies","volume":"11","author":"Sun","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2023100510362977200_ofad480-B2","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1007\/s11033-022-07160-3","article-title":"Risks of mucormycosis in the current COVID-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients","volume":"49","author":"Monika","year":"2022","journal-title":"Mol Biol Rep"},{"key":"2023100510362977200_ofad480-B3","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/cid\/ciw563","article-title":"Detection of circulating Mucorales DNA in critically ill burn patients: preliminary report of a screening strategy for early diagnosis and treatment","volume":"63","author":"Legrand","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023100510362977200_ofad480-B4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023100510362977200_ofad480-B5","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2666-5247(21)00237-8","article-title":"The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries","volume":"3","author":"Hoenigl","year":"2022","journal-title":"Lancet Microbe"},{"key":"2023100510362977200_ofad480-B6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2023100510362977200_ofad480-B7","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in Cooperation With the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2023100510362977200_ofad480-B8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","author":"Skiada","year":"2013","journal-title":"Haematologica"},{"key":"2023100510362977200_ofad480-B9","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2023100510362977200_ofad480-B10","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/AAC.01488-07","article-title":"Comparison of lipid amphotericin B preparations in treating murine zygomycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100510362977200_ofad480-B11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1399-3062.2006.00197.x","article-title":"Outcomes of invasive zygomycosis infections in renal transplant recipients","volume":"9","author":"Forrest","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"2023100510362977200_ofad480-B12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2023100510362977200_ofad480-B13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023100510362977200_ofad480-B14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cmi.2023.03.008","article-title":"COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases","volume":"29","author":"\u00d6zbek","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2023100510362977200_ofad480-B15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cmi.2016.01.005","article-title":"Mucormycosis in Australia: contemporary epidemiology and outcomes","volume":"22","author":"Kennedy","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2023100510362977200_ofad480-B16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/mmy\/myx017","article-title":"Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases","volume":"56","author":"Corzo-Le\u00f3n","year":"2018","journal-title":"Med Mycol"},{"issue":"Suppl 1","key":"2023100510362977200_ofad480-B17","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1093\/cid\/cir869","article-title":"Host defenses against zygomycetes","volume":"54","author":"Roilides","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2023100510362977200_ofad480-B18","doi-asserted-by":"crossref","first-page":"i39","DOI":"10.1093\/jac\/dkx032","article-title":"Invasive mould infections in the ICU setting: complexities and solutions","volume":"72","author":"Bassetti","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023100510362977200_ofad480-B19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9343(89)80836-8","article-title":"Mucormycosis: association with deferoxamine therapy","volume":"87","author":"Daly","year":"1989","journal-title":"Am J Med"},{"key":"2023100510362977200_ofad480-B20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/13693786.2012.669502","article-title":"Risk factors for mortality in patients with mucormycosis","volume":"50","author":"Spellberg","year":"2012","journal-title":"Med Mycol"},{"key":"2023100510362977200_ofad480-B21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QCO.0000000000000277","article-title":"Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents","volume":"29","author":"Chitasombat","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"2023100510362977200_ofad480-B22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/fmb-2022-0141","article-title":"Mucormycosis, past and present: a comprehensive review","volume":"18","author":"Gupta","year":"2023","journal-title":"Future Microbiol"},{"key":"2023100510362977200_ofad480-B23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/jof6040265","article-title":"Epidemiology and diagnosis of mucormycosis: an update","volume":"6","author":"Skiada","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2023100510362977200_ofad480-B24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes\u2014global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"2023100510362977200_ofad480-B25","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023100510362977200_ofad480-B26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The deferasirox-AmBisome therapy for mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J Antimicrob Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad480\/51723934\/ofad480.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/10\/ofad480\/51882380\/ofad480.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/10\/ofad480\/51882380\/ofad480.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T10:36:54Z","timestamp":1696502214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad480\/7280386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad480","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,9,21]]},"article-number":"ofad480"}}